Top Markets
Coin of the day
AIxCrypto Holdings, Inc. AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc.

AIXC
Rangering i aksjer #27458
AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company... AIxCrypto Holdings, Inc. is a clinical-stage biopharmaceutical company committed to discovering and developing innovative treatments for both adult and pediatric oncology. Its leading investigational therapeutic, QN-302, is a small molecule G-quadruplexes (G4)-selective transcription inhibitor currently progressing through Phase I clinical trials for pancreatic cancer and a range of other solid tumors. The firm is also advancing Pan-RAS, a preclinical-stage program targeting advanced solid tumors. Founded in 1996 and headquartered in Carlsbad, California, the company rebranded from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc. in November 2025.
Aksjekurs
$1.62
Sist synkronisert: 2026-08-19
Markedsverdi
$32.77M
Endring (1 dag)
22.67%
Endring (1 år)
-13.87%
Land
US
Handel AIxCrypto Holdings, Inc. (AIXC)

Kategori

P/B-forhold for AIxCrypto Holdings, Inc. (AIXC)
P/B-forhold per 2026 TTM: 0
Ifølge AIxCrypto Holdings, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for AIxCrypto Holdings, Inc. fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter